Member Info for EmeraldCarrots

.....

The MT-RNR1. It is completely mad they have not given this more priority. Would attract USA share holders. They need to put it in asap.

https://www.lse.co.uk/rns/GDR/breakthrough-device-designation-from-the-us-fda-2zclfstav7guqaq.html

Of these type of Companies don't seem to be?

BUT the placing would need to be taken into account which was 17% or so new shares. So 2.975 less about 17% (0.6) = 2.4p! So a bid would have to be a minimum of about 2.4p. I can easily see that happening (if correct!).

Actually a bid I think would have to be 2.975p being the highest the sp has been last 12 months. Is that right?

That would be nice.

I imagine catching the live, intact, uncontaminated CTC's with Parsortix would be needed so the protein expression could be measured to see if the candidate is suitable. This is a phase 3 trial. May be the making of Angle!!

All IMHO.

Can request FDA approval and then it could be on sale Worldwide!

A.I.

"Once a Phase III study is completed, a pharmaceutical company can request FDA approval to market the drug. This is called a New Drug Application (NDA).".

In GDR! LOL! That is why Gino went to that "Kings fund" event yesterday!!!! LOL!!!!!!!!!!

Going to bail us out? LOL!

He is usefull in many ways but dealmaking is not one of them. His track record speaks for itself.

This Immatics phase 3 trial mentioned in the results is extremely interesting. Uses Parsortix and 350 participants. What if Phase 3 gets the green light?? A phase IV with maybe 1500 participants or more?, or maybe if it passes phase 3 then it can go on sale?????

All IMHO.

Https://immatics.com/clinical-trials/

https://clinicaltrials.gov/study/NCT06743126

A protein that is expressed, so Parsortix neeed.

A.I PRAME.

PRAME, an acronym for "PReferentially expressed Antigen in Melanoma," is a tumor-associated antigen that is preferentially found in melanomas and other cancers, but normally only in specific tissues like the testes, ovaries, and placenta. It is a cancer-testis antigen (CTA) known for playing a role in cancer cell proliferation, metastasis, and apoptosis. PRAME also serves as a potential diagnostic marker, a prognostic indicator in some cancers, and a target for cancer immunotherapy.

Key Characteristics

Tumor Antigen:

PRAME is a protein that is expressed more frequently on cancer cells, particularly melanomas, than in normal tissues.

Cancer-Testis Antigen (CTA):

It belongs to the family of cancer-testis antigens, which are typically found in germ cells of the reproductive organs but are reactivated in various malignancies.

Cellular Function:

PRAME is involved in processes like cell proliferation, differentiation, and apoptosis (programmed cell death), and its presence can influence cancer progression.

Normal Tissue Expression:

Outside of cancer, its expression is generally restricted to the testes, ovaries, placenta, adrenal glands, and endometrium.

Applications of PRAME

Diagnostic Tool:

Detecting PRAME expression, often through immunohistochemistry (IHC) on tissue samples, helps pathologists diagnose melanocytic lesions and differentiate between benign nevi and malignant melanomas.

Prognostic Indicator:

Elevated PRAME expression can indicate a poor prognosis (worse outcome) in some cancers, though in other malignancies like certain leukemias, it might predict a more favorable outcome.

Immunotherapy Target:

Because it is tumor-specific and can be recognized by the immune system, PRAME is being investigated as a target for new cancer immunotherapies, such as PRAME-based vaccines and therapies that mobilize T-cells to attack cancer cells

Up 26.32%.

Https://immatics.com/clinical-trials/

https://clinicaltrials.gov/study/NCT06743126

FDA application.

- On second thoughts maybe a tad optimistic!

I think the market would like that, and the sp would stay around the 1.5p mark.

Hmm.

Any buyer will get a splendid deal IMHO. That is the way it goes. The NHS and NICE red tape has cost GDR millions IMHO. Now we are just about there a savvy buyer will make an offer and say "Thanks very much!".

All IMHO.

The two machines recomended and tested for use by NICE, and don't we know it! Likely some savvy buyer will make an offer and share holders will accept it as they have little choice. 2p to 2.5p a share is all we will get IMHO. If your average is above this then IMHO you will lose.

All IMHO.